Safety of unconventional antibody-drug conjugate L-DOS47 in a phase I/II monotherapy study targeting advanced NSCLC
Rodryg Ramlau, Gabrielle M. Siegers, Kazimierz Roszkowski‐Śliż, Cezary Szczylik et al.
Citations
1 citations
Journal
Frontiers in Oncology
Topics
Cancer, Hypoxia, and Metabolism
Field-Weighted Citation Impact (FWCI)
0.94
article
Safety of unconventional antibody-drug conjugate L-DOS47 in a phase I/II monotherapy study targeting advanced NSCLC
Rodryg Ramlau, Gabrielle M. Siegers, Kazimierz Roszkowski‐Śliż, Cezary Szczylik, Dariusz M. Kowalski, Young Ou, Kim Gaspar, Martin Köbel, Brenda Lee, Aleksandra Szczęsna
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Frontiers in OncologyVol. 15
Institutions
University of Calgary (CA), Masih Daneshvari Hospital (IR), Calgary Laboratory Services (CA), National Centre for Nuclear Research (PL), Helix Biopharma (Canada) (CA), Centrum Leczenia Oparzeń (PL), Instytut Technik Telekomunikacyjnych i Informatycznych (Poland) (PL), National Center for Tuberculosis and Lung Disease (GE), National Institute of Oncology (HU), The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Safety of unconventional antibody-drug conjugate L-DOS47 in a phase I/II monotherapy study targeting advanced NSCLC — Rodryg Ramlau, Gabrielle M. Siegers, et al. · Frontiers in Oncology (2025) | TGRS Research Map | TGRS